ALTERITY THERAPEUTICS

Alterity Therapeutics Reports Positive Efficacy Data for ATH434 in a Primate Model of Parkinson’s Disease

04 12月 2023 04:25:00 条件 Nasdaq GlobeNewswire

Alterity Therapeutics Announces Presentation of Novel Biomarker Data for Evaluation of Multiple System Atrophy

27 11月 2023 04:25:00 条件 Nasdaq GlobeNewswire

Alterity Therapeutics Announces Presentation of New Data Demonstrating Novel Mechanisms of ATH434

16 11月 2023 04:25:00 条件 Nasdaq GlobeNewswire

Alterity Therapeutics Completes Enrolment in ATH434-201 Phase 2 Clinical Trial in Multiple System Atrophy

08 11月 2023 04:25:00 条件 Nasdaq GlobeNewswire

Appendix 4C – Q1 FY24 Quarterly Cash Flow Report

30 10月 2023 04:25:00 条件 Nasdaq GlobeNewswire

Alterity Therapeutics Presents New Data on Multiple System Atrophy, a Rare Parkinsonian Disorder

31 8月 2023 04:25:00 条件 Nasdaq GlobeNewswire

Alterity Therapeutics Granted New Composition of Matter Patent in Europe for Neurodegenerative Diseases including Parkinson’s and Alzheimer’s

23 8月 2023 04:25:00 条件 Nasdaq GlobeNewswire

Alterity Therapeutics Rare Disease Natural History Study to be Featured at the International Congress of Parkinson’s Disease and Movement Disorders

22 8月 2023 04:25:00 条件 Nasdaq GlobeNewswire

Alterity Therapeutics Receives a $4.74 million Research & Development Tax Incentive Refund

15 8月 2023 04:25:00 条件 Nasdaq GlobeNewswire

Appendix 4C – Q4 FY23 Quarterly Cash Flow Report

31 7月 2023 04:52:00 条件 Nasdaq GlobeNewswire

Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned

26 7月 2023 04:25:00 条件 Nasdaq GlobeNewswire

Alterity Therapeutics to Present in MST Access Rare Diseases, Rich Returns Forum on 22 June 2023

21 6月 2023 04:25:00 条件 Nasdaq GlobeNewswire

Alterity Therapeutics Initiates Second Phase 2 Study in Rare Parkinsonian Disorder

30 5月 2023 04:25:00 条件 Nasdaq GlobeNewswire

Alterity Therapeutics CEO David Stamler to Present at the SHARE Series Monday Management Update on Monday, May 22, 2023

19 5月 2023 04:25:00 条件 Nasdaq GlobeNewswire

Alterity Therapeutics Enrolls First Patient in Australia in ATH434 Global Phase 2 Clinical Trial in Multiple System Atrophy

10 5月 2023 04:25:00 条件 Nasdaq GlobeNewswire

Appendix 4C – Q3 FY23 Quarterly Cash Flow Report

10 5月 2023 04:25:00 条件 Nasdaq GlobeNewswire

Alterity Therapeutics Presents Promising Wearable Sensor Data from the bioMUSE Natural History Study at the American Academy of Neurology

26 4月 2023 04:25:00 条件 Nasdaq GlobeNewswire

Alterity Therapeutics Enrolls First Patient in the United Kingdom in ATH434 Phase 2 Clinical Trial in Multiple System Atrophy

04 4月 2023 04:25:00 条件 Nasdaq GlobeNewswire

Alterity Therapeutics Enrolls First Patient in the U.S. in ATH434 Phase 2 Clinical Trial in Multiple System Atrophy

16 3月 2023 04:25:00 条件 Nasdaq GlobeNewswire

Alterity Therapeutics Announces Granting of New Composition of Matter Patent and Exclusive License Agreement for Assets in Alzheimer’s Disease

14 3月 2023 04:25:00 条件 Nasdaq GlobeNewswire